Crystal Structure of Human Aurora B in Complex with INCENP and VX-680 by J. Elkins et al.
Crystal Structure of Human Aurora B in Complex with INCENP and
VX-680
Jonathan M. Elkins,*,† Stefano Santaguida,‡,⊥ Andrea Musacchio,‡,§,∥ and Stefan Knapp†
†Nuﬃeld Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Old Road Campus Research
Building, Roosevelt Drive, Oxford, OX3 7DQ, United Kingdom
‡Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy
§Department of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Straße 11, 44227 Dortmund,
Germany
∥Centre for Medical Biotechnology, Faculty of Biology, University Duisburg-Essen, Universitaẗsstrasse, 45141 Essen, Germany
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ABSTRACT: We present the structure of the human Aurora B kinase domain
in complex with the C-terminal Aurora-binding region of human INCENP and
the Aurora kinase inhibitor VX-680. The structure unexpectedly reveals a
dimeric arrangement of the Aurora B:INCENP complex, which was conﬁrmed
to exist in solution by analytical ultracentrifugation. The dimerization involves
a domain swap of the activation loop, resulting in a diﬀerent conformation of
the DFG motif as compared to that seen in other kinase complexes with VX-
680. The binding of INCENP diﬀers signiﬁcantly from that seen in the
Xenopus laevis Aurora B:INCENP complex currently used as a model for structure-based design for this important oncology
target.
■ INTRODUCTION
Mammals express three Aurora kinases, Aurora A, Aurora B,
and Aurora C, encoded by the genes AURKA, AURKB, and
AURKC. Aurora C expression is mainly restricted to testis,
where it functions during meiosis, whereas Aurora A and B play
key functions regulating mitosis. Aurora A is localized to the
centrosome and spindle poles, where it drives centrosome
maturation, separation, and bipolar spindle assembly. Aurora B
is the central component of the chromosomal passenger
complex (CPC) that also contains the inner centromere
protein (INCENP), borealin, and survivin. These non-
enzymatic components of the CPC play a key role in regulating
kinase activity and localization.1,2 The Aurora kinases are
related to the AGC (protein kinase A, protein kinase G, and
protein kinase C) branch of protein kinases.3 Part of the
activation mechanism for most AGC kinases is mediated by
binding of the phosphorylated C-terminal “hydrophobic motif”,
FXXF(T/S)F, to the N-terminal lobe of the kinase catalytic
domain. However, Aurora kinases lack canonical C-terminal
hydrophobic motifs and are activated in trans through binding
of regulatory proteins to their N-terminal lobe. Aurora A is
activated through interaction with TPX2. For Aurora B and
Aurora C, the C-terminal section of the INCENP protein (the
“IN-box”) performs a similar regulatory function.4
The structure of human Aurora A has been determined both
without TPX25,6 and in complex with TPX2.7 The structure of
Aurora B has previously been determined from Xenopus laevis,
in complex with INCENP and the Aurora B inhibitor
hesperadin8 as well as other inhibitors.9−12 Human Aurora B
is 80% identical to X. laevis Aurora B over the kinase domain
(55−344) and 72% identical to human Aurora A over the
kinase domain. Human INCENP is 50% identical to X. laevis
INCENP over the region 835−903 that is involved in binding
to Aurora B.
Aurora A phosphorylated on the activation loop in the
absence of TPX2 has been observed in both active6 and inactive
conformations.5,6 Aurora A has been cocrystallized together
with 1 (VX-680, Figure 1) in the presence of TPX2, which
caused binding to an active kinase conformation,13 and also in
the absence of TPX2, which caused 1 to bind to an inactive
conformation of the kinase domain,14 although this latter
structure is not yet available in the Protein Data Bank.
Aurora B is activated by phosphorylation of both Aurora B
and INCENP. First, phosphorylation of INCENP at the TSS
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Figure 1. Chemical structure of compound 1 (VX-680).
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motif of the C-terminal IN-box region, which can be performed
by Aurora B itself, is important for full activity.8,15 Second,
autophosphorylation on the activation loop of Aurora B (for
human Aurora B at Thr232) produces the active kinase.8 A
recent study showed that phosphorylation on Ser331 of Aurora
B by Chk1 was essential for phosphorylation of the TSS motif
of INCENP and also for full activation of Aurora B.16
Although most genetic alterations identiﬁed in cancer involve
the Aurora A locus, high expression levels of Aurora B have
been detected and associated with poor prognosis in
glioblastoma, ovarian carcinoma, and hepatocellular carcinoma.
Inhibition of Aurora B leads to failure to biorientate
chromosomes and massive polyploidization. As a result of the
induced chromosomal defects, both p53-proﬁcient and p53-
deﬁcient cells undergo apoptosis. Aurora B has therefore
become an extensively pursued anticancer target,17 and many
Aurora inhibitors have been developed, including recently some
isoform-speciﬁc inhibitors.18−22 The Aurora kinase inhibitors
(second generation type 2 inhibitors) such as 123 have
considerable antitumor activity. Compound 1 also inhibits
some other kinases, notably the tyrosine kinase ABL, and
crystal structures have been solved for 1 bound to ABL124 and
ABL2.25
To provide a model for structure-based design and to gain
insight into the molecular mechanism of human Aurora B
activation, we determined the structure of human Aurora B
kinase domain, in complex with the C-terminal IN-box section
of human INCENP (residues 835−903) and the type II
inhibitor 1 (Figure 1).
■ RESULTS
Structure Determination. We began structural studies on
human Aurora B by preparing a set of constructs spanning
diﬀerent ranges of the gene, all of which included the kinase
domain, for overexpression in Escherichia coli. From this set,
three constructs (55−344, 65−344, and 70−344) expressed
large amounts of soluble protein. However, all of these proteins
precipitated shortly after Ni2+-aﬃnity puriﬁcation. Therefore, a
bacterial expression construct for the C-terminal part of human
INCENP was prepared, spanning residues 835−903, which is
the Aurora-binding region. This expression construct contained
a glutathione-S-transferase puriﬁcation tag to enable sequential
aﬃnity puriﬁcation of the heterodimeric Aurora B:INCENP
complex by sequential Ni2+-aﬃnity followed by glutathione
sepharose aﬃnity chromatography. The two proteins were
expressed separately, and the cells were mixed before lysis and
subsequent protein puriﬁcation. The Aurora B protein was
monophosphorylated according to electrospray ionization mass
spectrometry (data not shown). Using this puriﬁed protein, we
were able to cocrystallize the Aurora B INCENP heterodimer
in complex with the type II inhibitor 1 and determine the
structure to a resolution of 2.75 Å (Table 1).
Structure of Human Aurora B. As expected from the
primary sequence similarities, the overall structure of human
Aurora B resembles the structures of X. laevis Aurora B and
human Aurora A, with the exception of the conformation of the
activation loop (Figure 2). Unexpectedly, a domain swap was
observed; part of the kinase activation loop was exchanged
between two Aurora B molecules in the crystal lattice, resulting
in similar binding of the activation loop against the C-terminal
lobe of the kinase but diﬀerent conformations around the DFG
(Asp-Phe-Gly) motif at the start of the activation loop (Figure
3A). Although this is a feature that has been observed before in
kinase crystal structures,26−28 to our knowledge, this is the ﬁrst
time it has been observed in an Aurora kinase structure.
Activation loop exchange has been suggested as an activation
mechanism for kinases that autoactivate on nonconsensus
binding sites in their activation segment. In the Aurora
B:INCENP complex, the activation segment is disordered
after the DFG motif, including the phosphorylation site
Thr232. The C-terminal part of the activation segment is
dislodged from the lower lobe and interacts with a deep groove
generated by the displaced activation segment in the interacting
protomer. Overall, there is a buried surface area of interaction
of 3460 Å2, and the segment is anchored mainly by aromatic
and hydrophobic interactions of Y239, L237, Pro242, and I245
(Figure 3C,D).
The electron density unambiguously favored the loop-
exchanged arrangement over the alternative model of a
conventional arrangement (Figure 3B). The residues at the
point of the domain swap form more favorable interactions
than they would have in the case of a nonexchanged
arrangement (Figure 3B). In particular, there is a favorable
hydrophobic packing of the side chain of Met249 with Met244
and a favorable interaction of His250 with His198.
Met249, which is important for the formation of the domain-
swapped form, is not conserved in X. laevis Aurora B, which has
Thr265 instead. Apart from one conservative substitution of an
arginine for a lysine, this is the only diﬀerence in the activation
loop between the human and X. laevis enzymes, which is one of
the most highly conserved regions in the whole protein. Given
the very favorable nature of the hydrophobic packing of the
Met249 side chain, it may be that this single amino acid
diﬀerence is responsible for the observation of a domain
swapped dimeric form of Aurora B only for crystals of the
human orthologue.
In this domain-swapped arrangement, part of the activation
loop packs against the outside of helix αC, which is important
for the activity and regulation of protein kinases. Whether this
arrangement has any eﬀect on the activity or regulation of
human Aurora B kinase is an open question, but it may be
partly responsible for the outward movement of αC relative to
the structures of X. laevis Aurora B with 1 and ABL1/2 with 1
(discussed below).
Oligomeric State Distribution. After observing the
activation loop in the domain swapped conformation, to see
if the dimeric state was also observed in solution, we analyzed
the oligomeric state of the complex by analytical ultra-
Table 1. Data Collection and Reﬁnement Statistics
unit cell [a, b, and c (Å); α, β, and γ (deg)] 80.1, 80.1, 92.5, 90.0, 90.0, 120.0
space group P3121
no. of molecules/asu 1
data collection
resolution rangea (Å) 19.58−2.75 (2.90−2.75)
completenessa (%) 99.7 (100.0)
multiplicitya 11.8 (7.0)
Rmerge
a (%) 0.082 (0.936)
⟨I/σ(I)⟩a 22.6 (2.0)
reﬁnement
R factor (%) 20.5
Rfree (%) 26.4
rmsd bond length (Å) [angle (°)] 0.008 (1.22)
PDB ID 4AF3
aValues in parentheses are for the highest resolution shell.
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centrifugation (AUC). A sedimentation velocity experiment
showed the presence of both monomer and dimer, with the
majority of the sample being dimeric (Figure 4). As the
monomer and dimer had diﬀerent frictional ratios ( f/f 0), the
data were modeled as a dual distribution of s and f/f 0.
29 The
sedimentation velocity analysis gave molecular weights of
43307 and 81882 for the two species present, which compared
well with the expected values of 41849 and 83680 for monomer
and dimer based on the protein sequences. The frictional ratio
for the dimeric species was higher at 2.09, as compared to 1.94
for the monomeric species, corresponding to a less spherical
dimeric arrangement. Integration of the distribution resulted in
values of 54% dimer and 31% monomer, plus 11% of a species
Figure 2. Overview of human Aurora B kinase as compared to X. laevis Aurora B and human Aurora A. (A) Human Aurora B with INCENP colored
green and the activation loop colored red. (B) X. laevis Aurora B complex with Hesperadin (PDB ID: 2BFY),8 with INCENP colored green and the
activation loop colored red. (C) Human Aurora A complex with 1 (PDB ID: 3E5A),13 with TPX2 colored green and the activation loop colored red.
Figure 3. Activation loop exchange of Aurora B kinase. (A) The two Aurora B molecules in the dimer are colored in yellow and blue, INCENP is
green, and the activation loops are colored red with dashed lines to indicate where the disordered residues would form a connection. Part of the
activation loop packs against the αC helix. (B) The electron density at the cross-over point for the domain swap. The two molecules of Aurora B are
colored in orange and blue. The dashed lines in red indicate the connections that would be made between Met249 and His250 in the absence of a
domain swap. (C) As in panel A but with one Aurora B:INCENP molecule displayed as a surface, showing the binding of the activation loop in the
dimeric arrangement. (D) The activation loop residues involved in the binding.
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of approximately 49 kDa with a signiﬁcantly lower frictional
ratio than the peaks assigned as monomer and dimer.
Interface between Aurora B and INCENP. The C-
terminal part of INCENP, the IN-box, wraps around the N-
terminal lobe of the Aurora B kinase domain in a manner
similar to that seen previously with the X. laevis orthologue.
The two proteins are 50% identical over the region used in the
construct for crystallization (835−903) (Figure 5A). However,
although the binding of the N-terminal part of the N-box
(residues 842−863, “site 1”) closely resembles that of the X.
laevis Aurora B INCENP structure (Figure 5B), the C-terminal
part (residues 868−881, “site 2”) is mostly diﬀerent, with a
substantial variation in the backbone conformation of the
INCENP residues at site 2 (Figure 5C). At site 1, the INCENP
backbone adopts the same α-helical arrangement, with the only
signiﬁcant diﬀerences in binding being for the nonconserved
residues Ile856 of INCENP and Leu210 of Aurora B, which are
Arg812 and Tyr228 in the X. laevis orthologue. The human
complex therefore has a hydrophobic interaction at this point in
place of the hydrogen bond between the Tyr and the Arg side
chains in X. laevis.
At site 2, the INCENP backbone adopts a diﬀerent
conformation with only the binding of the very C-terminal
Phe881 conserved (Figure 5C). Furthermore, the Aurora αC
helix is displaced relative to the rest of the Aurora structure.
The binding is largely composed of hydrophobic interactions,
Figure 4. Sedimentation velocity analysis of AuroraB:INCENP,
showing a 2D plot of f/f 0 on the Y-axis and s on the X-axis. The
smaller and larger peaks correspond to monomeric and dimeric
AuroraB:INCENP, respectively. Peak height is indicated by color on a
scale from blue to red (strongest).
Figure 5. Interface between Aurora B kinase and INCENP. (A) Sequence alignment of human and X. laevis INCENP over the C-terminal IN-box
region. (B) Comparison of human and X. laevis Aurora B:INCENP binding at site 1 (residues 842−863 of human INCENP) showing the mostly
conserved interactions, with two exceptions highlighted. The X. laevis Aurora B and INCENP are colored blue and purple, respectively (X. laevis
coordinates were taken from PDB ID 2BFX8). (C) Comparison of human and X. laevis Aurora B:INCENP binding at site 2 (residues 868−881 of
human INCENP) showing the mostly nonconserved binding conformation, with the exception of the terminal Phe881. (D) Binding detail for site 2
of human Aurora B:INCENP.
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particularly those around INCENP Leu875 and Leu877 (Figure
5D). Leu875 is replaced by a proline in X. laevis INCENP.
There is also a hydrogen bond between the Aurora B Tyr145 (a
histidine in X. laevis Aurora B) and the INCENP backbone
(Figure 5D).
Aurora B:1 Has a Diﬀerent αC and DFG Conformation
as Compared to Aurora A and X. laevis Aurora B.
Compound 1 binds to human Aurora B in a similar
conformation to that seen in complexes with other kinases. A
structure of X. laevis Aurora B bound to 1 is not available, so the
structural comparisons of 1 binding considered here are
restricted to the published structures of Aurora A:1 (PDB
ID: 3E5A)13 and ABL2:1 (PDB ID: 2XYN).25 A structure of an
imatinib-resistant mutant ABL1 in complex with 1 is also
available.24
The glycine-rich loop of Aurora B is in a diﬀerent
conformation to that of Aurora A in the region around
Phe88 (Figure 6A,B). It adopts a conformation similar to the
glycine-rich loop of ABL2 when bound to 1 (Figure 6A,C),
although ABL2 has Tyr299 in place of Phe88 of Aurora B.
However, the most signiﬁcant diﬀerence between Aurora A and
Aurora B when bound to 1 is in the arrangement of the DFG
motif. In Aurora A, the DFG motif is arranged with the Phe
underneath the αC helix, while in Aurora B, the αC helix is
moved further out from the ATP site and the DFG Phe is to
the side of the helix with the Asp not well-ordered in the
structure (Figure 6D). As ABL1/2 also have a similar
arrangement of the DFG Phe and αC as Aurora A, Aurora B
diﬀers from all of these when bound to 1. The movement out
of αC allows more positional options for the Aurora B DFG
motif and also a potentially bigger “back pocket” for inhibitor
binding than in Aurora A, although due to the placement of the
DFG Phe the pocket in this particular structure is slightly
smaller.
Comparison of Inhibition of Human and X. laevis
Aurora B. Comparison of the IC50 values for inhibition X.
laevis Aurora B by three common Aurora kinase inhibitors with
the previously published IC50 values for inhibition of human
Aurora B by the same three inhibitors30 shows that Aurora B
from both species behaves almost identically (Table 2).
■ DISCUSSION
Aurora kinases have been pursued as drug targets for some
time, particularly in oncology. X-ray crystal structures of Aurora
A and Aurora B have been used extensively to advise medicinal
chemistry eﬀorts, either through ligand-bound structures or
through their use in molecular modeling. Until now, there has
not been a structure of human Aurora B kinase in the public
domain, and the X. laevis orthologue has been used instead.
It has been predicted previously that the binding site of
Aurora A:TPX2 has a smaller hydrophobic back pocket than
that of Aurora B:INCENP.19,31 Eﬀorts to develop Aurora
isoform-speciﬁc inhibitors have naturally focused on this region
as well as on the diﬀerences at the entrance to the ATP binding
site.10,18−21 The Aurora B structure presented here allows direct
comparison with an Aurora A structure with the same inhibitor
and conﬁrms that the hydrophobic back pocket of Aurora B is
indeed larger but with the caveat that the more outward
position of αC allows other conformations of the DFG motif,
which may favor or disfavor particular inhibitors.
Figure 6. Comparison of binding to 1 by Aurora B, Aurora A, and ABL2. (A) Aurora B:1. (B) Aurora A:1 (PDB ID: 3E5A).13 (C) ABL2:1 (PDB
ID: 2XYN).25 (D) Overlay of the DFG motifs of the complexes with 1 of Aurora B (in yellow) and Aurora A (in pink). (E) Overlay of the DFG
motifs of the complexes with 1 of Aurora B (in yellow) and ABL2 (in blue).
Table 2. IC50 Values (nM) for Inhibition of Human and X.
laevis Aurora B by Three Aurora Kinase Inhibitorsa
Hs Aurora B/
INCENP
Xl Aurora B/
INCENP
Hs Aurora A/
TPX2
hesperadin 3 3 11
1 31 19 15
ZM447439 51 45 360
aData on the human enzymes from Santaguida et al.30 Binding curves
can be found in the Supporting Information.
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The more outward position of αC is so far unique to human
Aurora B; all of the X. laevis Aurora B cocrystal structures so far
deposited in the PDB have a similar αC position, even with the
inhibitor ZM447439, which binds much further into the
hydrophobic pocket than 1 (PDB ID: 2VRX9), although it
should be noted that the structure with ZM447439 was
obtained by soaking Aurora B:INCENP crystals with the
compound, and a diﬀerent structure could possibly have arisen
by cocrystallization. For Aurora A in the absence of TPX2, even
further outward positions of αC have been observed, both with
type II compounds that extend signiﬁcantly into the hydro-
phobic pocket [e.g., PDB ID: 3DJ6 (mouse Aurora A)] and
with compounds that do not (e.g., PDB ID: 2WTV or 3UNZ).
In both of the structures of Aurora A in complex with TPX2
(which binds on the outside of αC), αC adopts an inward
position.
The dimerization of Aurora B:INCENP that we have
observed both in the crystal structure and in solution is
probably the most signiﬁcant factor in the diﬀerent DFG motif
arrangement of this complex with 1 as compared to those of
Aurora A or ABL. The domain swap involves a very diﬀerent
conformation of the activation loop, which is most likely the
cause of the diﬀerent DFG position. It is unclear to what extent
diﬀerent inhibitors might promote or hinder dimerization. The
AUC experiments showed dimerization in the absence of an
inhibitor, so compound 1 was not the cause of the observed
dimerization in the crystal structure. However, because the
dimerization interface involves αC and is dependent on the
activation loop, an inhibitor that promotes a substantially
diﬀerent αC position or DFG position could conceivably
promote or hinder dimerization.
The variation of INCENP binding between the human and
the X. laevis orthologues at the second site next to αC is
probably a feature of the irregular backbone conformation. By
contrast, at the ﬁrst binding site, INCENP has an invariant α-
helical backbone conformation, which inevitably leads to a
more conserved binding arrangement. Whether INCENP can
adopt diﬀerent conformations at the second site to accom-
modate movements of αC during activation (or inhibition) of
Aurora B is a question that has to be explored in the future.
■ MATERIALS AND METHODS
Cloning. DNA for residues 55−344 of the kinase domain of human
AURKB (gi|83776600) was PCR ampliﬁed from DNA in the
Mammalian Gene Collection (IMAGE ID 2819846) and inserted
into vector pNIC28-Bsa4 (which carries kanamycin resistance)32 in-
frame with an N-terminal hexahistidine puriﬁcation tag and TEV
protease cleavage site, by ligation-independent cloning. DNA for
residues 835−903 of human INCENP (gi|102467235, inner
centromere protein isoform 1) was PCR ampliﬁed from INCENP
cDNA and inserted into vector pGTvL1-SGC (which carries ampicillin
resistance) in-frame with an N-terminal glutathione S-transferase
puriﬁcation tag and TEV protease cleavage site, also by ligation-
independent cloning. These plasmids were each transformed
separately into chemically competent E. coli BL21 (DE3) containing
a plasmid for expression of rare tRNAs.
Protein Expression and Puriﬁcation of Aurora B:INCENP
Complex. Colonies from the transformation were used to inoculate
LB media containing 34 μg/mL chloramphenicol and either 100 μg/
mL ampicillin (for INCENP) or 50 μg/mL kanamycin (for Aurora B).
The cultures were grown overnight in baﬄed shaker ﬂasks at 37 °C
with shaking. These cultures were used to inoculate TB media by
adding 15 mL of culture to 1 L of TB (containing either 80 μg/mL
ampicillin or 40 μg/mL kanamycin) in baﬄed shaker ﬂasks. When the
cultures had an OD600 of approximately 1.2, the temperature was
reduced to 20 °C. After a further 25 min, protein expression was
induced by addition of isopropyl β-D-1-thiogalactopyranoside to 0.5
mM. The cultures were left shaking at 20 °C overnight before the cell
pellets were harvested by centrifugation. The cells were resuspended in
Binding Buﬀer (20 mM imidazole, 200 mM NaCl, and 50 mM Tris,
pH 7.8) with the addition of 0.5 mM tris(2-carboxyethyl)phosphine
(TCEP) and protease inhibitor cocktail (Sigma). The resuspended
cells were stored at −20 °C.
For protein puriﬁcation, the resuspended cells for the Aurora B and
INCENP expressions were combined and thawed together (4 L of
culture of Aurora B and 6 L of culture of INCENP). The combined
cells were lysed with a high-pressure homogenizer (Avestin).
Polyethyleneimine was added to a concentration of 0.15%, and the
lysate was centrifuged at 38000g for 20 min at 4 °C. The supernatant
was ﬁltered and loaded onto 10 mL of nickel-chelating resin. The resin
was washed with Binding Buﬀer and with Binding Buﬀer containing 40
mM imidazole. The protein was eluted with Binding Buﬀer containing
250 mM imidazole, and the eluate was loaded onto a column of 10 mL
of glutathione sepharose 4B resin (GE Healthcare). This resin was
washed with Binding Buﬀer before the protein was eluted with Binding
Buﬀer containing 10 mM reduced glutathione. The hexahistidine and
GST tags were removed by overnight treatment with TEV protease at
4 °C. The digested sample was concentrated to 4 mL volume and
loaded onto a Superdex75 gel ﬁltration column (HiLoad 16/60, GE
Healthcare) pre-equilibrated in GF Buﬀer (20 mM Hepes, pH 7.5, 200
mM NaCl, and 0.5 mM TCEP). Fractions from the gel ﬁltration
containing the desired AuroraB:INCENP complex were pooled and
passed through a column of 1 mL of glutathione Sepharose 4B and
then loaded onto a column of 0.7 mL of nickel-chelating resin. This
resin was eluted with 5 mL each of GF Buﬀer containing 20, 40, 60, 80,
100, and ﬁnally 120 mM imidazole. The desired protein complex
appeared in the 40−120 mM imidazole fractions. These fractions were
pooled, compound 1 was added, and the sample was twice
concentrated to 250 μL and then diluted to 4 mL with GF Buﬀer.
Finally, the sample was concentrated to 200 μL volume at which the
protein concentration was 6 mg/mL.
The protein identities were veriﬁed by electrospray ionization time-
of-ﬂight mass spectrometry (Agilent LC/MSD). The observed mass of
Aurora B showed between 1 and 4 phosphorylations.
Crystallization and Data Collection. The AuroraB:INCENP:1
complex (PDB ID: 4AF3) was crystallized at 20 °C in 300 nL drops
from a 2:1 ratio of AuroraB:INCENP:1 (6 mg/mL protein) and
reservoir solution (10% w/v PEG3350, 0.2 M KSCN, 10% ethylene
glycol, and 0.1 M BisTrisPropane, pH 6.15). The crystals were
cryoprotected in reservoir solution with 25% (v/v) ethylene glycol and
ﬂash-frozen in liquid nitrogen. X-ray diﬀraction data were collected at
100 K on beamline I04 at DIAMOND.
Structure Determination and Reﬁnement. The diﬀraction
images were processed using XDS33 and the CCP4 suite of
programs.34,35 The structure was solved by molecular replacement
using PHASER36 with the structure of X. laevis Aurora B (PDB ID:
2BFX) as a search model. The structure was reﬁned against maximum
likelihood targets using restrained reﬁnement and TLS parameters, as
implemented in the program REFMAC.37 Positive diﬀerence electron
density for the INCENP protein component and the inhibitor 1 was
visible in the initial maps. Iterative rounds of reﬁnement were
interspersed with manual rebuilding of the model using COOT.38
Progress of the reﬁnement was judged throughout by following a
reduction in Rfree (calculated from a random 5% of the data that was
excluded from the reﬁnement).
AUC. Sedimentation velocity measurements were made at 40000
rpm with a Beckman An50 Ti rotor in a Beckman XL-1 ultracentrifuge
at 4 °C. The protein sample was dialyzed overnight in 20 mM Hepes,
pH 7.5, 200 mM NaCl, and 0.5 mM TCEP, and the protein
concentration was 1.4 mg/mL for measurements. Absorbance data
(280 nm) were analyzed using SEDFIT.39,40
Activity Measurements. Kinase assays were performed as
previously described.15 Brieﬂy, reaction mixes contained 50 μM
ATP, 1 mM DTT, 1 mM Na3VO4, 5 μCi γ-[
32P]ATP, 1 μg of histone
H3 as substrate, 1 μL of DMSO or drugs dissolved in DMSO, and the
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm3008954 | J. Med. Chem. 2012, 55, 7841−78487846
indicated kinases. Reaction mixes were incubated for 1 h at 30 °C,
quenched with SDS loading buﬀer, and resolved on 14% SDS-PAGE.
Incorporation of 32P was visualized by autoradiography. Densitometry
analysis was performed using ImageJ software (National Institutes of
Health). IC50 values were calculated from log−dose response curves
using Prism 4 software (GraphPad Software, Inc.).
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